Peritonitis: Difference between revisions
From IDWiki
(Created page with "== Clinical Presentation == === Primary peritonitis === * See Spontaneous bacterial peritonitis === Secondary peritonitis === * Secondary to trauma or perforation === Te...") |
m (Text replacement - "Clinical Presentation" to "Clinical Manifestations") |
||
| Line 1: | Line 1: | ||
== Clinical |
== Clinical Manifestations == |
||
=== Primary peritonitis === |
=== Primary peritonitis === |
||
* See [[Spontaneous bacterial peritonitis]] |
* See [[Spontaneous bacterial peritonitis]] |
||
Revision as of 19:29, 22 July 2020
Clinical Manifestations
Primary peritonitis
Secondary peritonitis
- Secondary to trauma or perforation
Tertiary peritonitis
- Ongoing intraabdominal sepsis after appropriate treatment of secondary peritonitis
- Organisms include resistant Gram-positives (Enterococcus, coagulase-negative Staphylococci), resistant Gram-negatives (ESBLs), and Candida
- Can also be aseptic without infection but with ongoing inflammation
Management
- Primary: see spontaneous bacterial peritonitis management
- Secondary:
- Source control
- Broad-spectrum antibiotics
- See also STOP IT trial for 4+/-1 days of antibiotics after source control
References
- ^ Robert G. Sawyer, Jeffrey A. Claridge, Avery B. Nathens, Ori D. Rotstein, Therese M. Duane, Heather L. Evans, Charles H. Cook, Patrick J. O’Neill, John E. Mazuski, Reza Askari, Mark A. Wilson, Lena M. Napolitano, Nicholas Namias, Preston R. Miller, E. Patchen Dellinger, Christopher M. Watson, Raul Coimbra, Daniel L. Dent, Stephen F. Lowry, Christine S. Cocanour, Michaela A. West, Kaysie L. Banton, William G. Cheadle, Pamela A. Lipsett, Christopher A. Guidry, Kimberley Popovsky. Trial of Short-Course Antimicrobial Therapy for Intraabdominal Infection. New England Journal of Medicine. 2015;372(21):1996-2005. doi:10.1056/nejmoa1411162.
